11 Long COVID Clinical Trials
Please fill out our 6-question evaluative survey HERE.
Learning Objectives
- Appreciate the range of strategies currently being used in the development of novel treatments for Long COVID, including consensus biomarker identification and monoclonal antibody approaches
- Understand pathophysiological hypotheses underlying Long COVID drug development
- Identify key experimental strategies used by the LIINC study to accelerate Long COVID research productivity
Video Module: Long COVID Clinical Trials
Faculty:
- Michael Peluso, MD, MHS – Assistant Professor, Medicine at University of California, San Francisco
Students:
- Mehr Grewal – University of Washington
Additional Resources & Further Reading
- AAPM&R Guidelines: Cheng AL, Herman E, Abramoff B, et al. Multidisciplinary collaborative guidance on the assessment and treatment of patients with Long COVID: A compendium statement. PM&R. 2025; 17(6): 684-708. doi:10.1002/pmrj.13397
- Long-term Impact of Infection with Novel Coronavirus (LIINC) study
- Geng LN, Erlandson KM, Hornig M, Letts R, Selvaggi C, Ashktorab H et al.; RECOVER Consortium. 2024 Update of the RECOVER-Adult Long COVID Research Index. JAMA. 2025 Feb 25;333(8):694-700. doi: 10.1001/jama.2024.24184. PMID: 39693079; PMCID: PMC11862971.
- Thaweethai T, Jolley SE, Karlson EW, Levitan EB, Levy B, McComsey GA, McCorkell L, Nadkarni GN et al.; RECOVER Consortium. Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection. JAMA. 2023 Jun 13;329(22):1934-1946. doi: 10.1001/jama.2023.8823. PMID: 37278994; PMCID: PMC10214179.
Self-Assessment
Test your knowledge with the following quiz questions: